The combination of PARP and PI3K inhibitors has been reported to be highly active in preclinical models (patient-derived xenografts and a Brca1/Trp53 knockout spontaneous genetically engineered mouse model) of breast cancer [13, 14]. This evidence concerns the gene BRCA1 and breast carcinoma.